Business
Virios Therapeutics Announces Second Quarter 2024 Financial Results
- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":"- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center’s Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the second quarter ended June 30, 2024. Key Highlights Completion of enrollment in the BHC-202 3-arm study, which is comparing two dose levels of the valacyclovir/celecoxib combination vs placebo over 12 weeks to treat symptoms of LC. BHC-202 is being conducted by the Bateman Horne Center under an unrestricted investigational grant provided by the Company. Top line results are expected in October 2024.Ongoing blinded safety analysis of the BHC-202 study indicates that study drug (either the combination of valacyclovir and celecoxib or matching placebo) has been very well tolerated to date with no serious adverse events reported, and only a few transient treatment emergent adverse events being reported.The Company completed a public offering with gross proceeds of $1.7 million to extend operational runway into Q1 2025.The Company continues to actively explore opportunities that will build shareholder value through strategic partnerships, collaborations or other transactions. “Epidemiologic research highlights that acute COVID-19 infections continue to outnumber flu cases and leads to higher levels of hospitalization and death” said R. Michael Gendreau, MD, Chief Medical Officer of Virios Therapeutics. “A recent study published in the New England Journal of Medicine highlights that Long-COVID sequelae still represents a significant unmet medical need, with unvaccinated patients more than twice as likely to develop Long-COVID following an acute infection. Decreasing vaccination rates suggest this unmet medical need will persist for the foreseeable future.” Second Quarter 2024 Financial Results Research and development expenses for the second quarter of 2024 were $0.3 million, compared t...